Bioavailability of Tc-99m-paclitaxel-glucuronide (Tc-99m-PAC-G)
dc.contributor.author | Muftuler, F. Z. Biber | |
dc.contributor.author | Demir, I. | |
dc.contributor.author | Unak, P. | |
dc.contributor.author | Ichedef, C. | |
dc.contributor.author | Kilcar, A. Yurt | |
dc.date.accessioned | 2019-10-27T21:28:01Z | |
dc.date.available | 2019-10-27T21:28:01Z | |
dc.date.issued | 2011 | |
dc.department | Ege Üniversitesi | en_US |
dc.description.abstract | An antitumor agent paclitaxel (PAC) has been proved to be efficient in the treatment of breast and ovarian cancer. Glucuronic acid-derived paclitaxel compound (paclitaxel-glucuronide (PAC-G)) was enzymatically synthesized using microsome preparate separated from rat livers. The biodistribution mechanism of PAC-G in healthy female Albino Wistar rats has been investigated. The expected structure is confirmed according to LC/MS results, and the possible attachment is to C2-hydroxyl group. PAC-G was labeled with Tc-99m and the radiochemical yield of radiolabeled compound (Tc-99m-PAC-G) was 98.00 +/- 2.74% (n = 9). The range of the breast/blood and breast/muscle ratios is approximately between 3 and 35 in 240 min. All these experimental studies indicate that Tc-99m-PAC-G may potentially be used in breast tissue as an imaging agent. | en_US |
dc.description.sponsorship | T.R. Prime Ministry State Planning Organization [06 DPT 06]; Ege UniversityEge University [2008 NBE 008] | en_US |
dc.description.sponsorship | We thank MS student Hasan ZORA and Eser UCAR for technical help. This work was supported by T.R. Prime Ministry State Planning Organization (contract no 06 DPT 06) and Ege University Research Fund (contract no 2008 NBE 008). | en_US |
dc.identifier.doi | 10.1524/ract.2011.1827 | |
dc.identifier.endpage | 306 | en_US |
dc.identifier.issn | 0033-8230 | |
dc.identifier.issn | 0033-8230 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.startpage | 301 | en_US |
dc.identifier.uri | https://doi.org/10.1524/ract.2011.1827 | |
dc.identifier.uri | https://hdl.handle.net/11454/45146 | |
dc.identifier.volume | 99 | en_US |
dc.identifier.wos | WOS:000290916400007 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.language.iso | en | en_US |
dc.publisher | Walter De Gruyter Gmbh | en_US |
dc.relation.ispartof | Radiochimica Acta | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Paclitaxel (PAC) | en_US |
dc.subject | Paclitaxel-glucuronide | en_US |
dc.subject | Tc-99m paclitaxel-glucuronide (Tc-99m-PAC-G) | en_US |
dc.title | Bioavailability of Tc-99m-paclitaxel-glucuronide (Tc-99m-PAC-G) | en_US |
dc.type | Article | en_US |